Differential drug-induced mRNA expression of human CYP3A4 compared to CYP3A5, CYP3A7 and CYP3A43KRUSEKOPF, Solveigh; ROOTS, Ivar; KLEEBERG, Ullrich et al.European journal of pharmacology. 2003, Vol 466, Num 1-2, pp 7-12, issn 0014-2999, 6 p.Article

CYP3A phenotypes and genotypes in North IndiansRAIS, Naushad; CHAWLA, Yogesh K; KOHLI, Krishan K et al.European journal of clinical pharmacology. 2006, Vol 62, Num 6, pp 417-422, issn 0031-6970, 6 p.Article

A Novel Biotransformation of Alkyl Aminopyrrolidine to Aminopiperidine Ring by Human CYP3AYUPING CHEN; SKILES, Gary L; SHOU, Magang et al.Drug metabolism and disposition. 2011, Vol 39, Num 9, pp 1668-1673, issn 0090-9556, 6 p.Article

NHIBITORY EFFECTS OF SCHISANDRIN A AND SCHISANDRIN B ON CYP3A ACTIVITYLI, W. L; XIN, H. W; SU, M. W et al.Methods and findings in experimental and clinical pharmacology. 2010, Vol 32, Num 3, pp 163-169, issn 0379-0355, 7 p.Article

Proluciferin Acetals as Bioluminogenic Substrates for Cytochrome P450 Activity and Probes for CYP3A InhibitionMEISENHEIMER, Poncho L; TETSUO UYEDA, H; DONGPING MA et al.Drug metabolism and disposition. 2011, Vol 39, Num 12, pp 2403-2410, issn 0090-9556, 8 p.Article

Potential Risk of Mulberry―Drug Interaction: Modulation on P-Glycoprotein and Cytochrome P450 3AHSU, Pei-Wen; SHIA, Chi-Sheng; LIN, Shiuan-Pey et al.Journal of agricultural and food chemistry (Print). 2013, Vol 61, Num 18, pp 4464-4469, issn 0021-8561, 6 p.Article

The development of a cocktail CYP2B6, CYP2C8, and CYP3A5 inhibition assay and a preliminary assessment of utility in a drug discovery settingO'DONNELL, Charles J; GRIME, Ken; COURTNEY, Paul et al.Drug metabolism and disposition. 2007, Vol 35, Num 3, pp 381-385, issn 0090-9556, 5 p.Article

Selective metabolism of vincristine in vitro by CYP3A5DENNISON, Jennifer B; KULANTHAIVEL, Palaniappan; BARBUCH, Robert J et al.Drug metabolism and disposition. 2006, Vol 34, Num 8, pp 1317-1327, issn 0090-9556, 11 p.Article

Determining theTime Course of CYP3A Inhibition by Potent Reversible and Irreversible CYP3A Inhibitors Using A Limited Sampling StrategyKATZENMAIER, S; MARKERT, C; RIEDEL, K.-D et al.Clinical pharmacology and therapeutics. 2011, Vol 90, Num 5, pp 666-673, issn 0009-9236, 8 p.Article

Retinoids activate RXR/CAR-mediated pathway and induce CYP3ASHIYONG CHEN; KUN WANG; WAN, Yu-Jui Yvonne et al.Biochemical pharmacology. 2010, Vol 79, Num 2, pp 270-276, issn 0006-2952, 7 p.Article

Expression of the CYP3A and CYP2C11 enzymes in a nutritionally obese rodent model : response to phenobarbital treatmentZANNIKOS, P. N; BANDYOPADHYAY, A. M; ROBERTSON, L. W et al.International journal of obesity. 1994, Vol 18, Num 6, pp 369-374, issn 0307-0565Article

Developmental Changes in the Expression and Function of Cytochrome P450 3A Isoforms: Evidence from In Vitro and In Vivo InvestigationsINCE, Ibrahim; KNIBBE, Catherijne A. J; DANHOF, Meindert et al.Clinical pharmacokinetics. 2013, Vol 52, Num 5, pp 333-345, issn 0312-5963, 13 p.Article

Expression of cytochromes P450 3A and P-glycoprotein in human large intestine in paired tumour and normal samplesCANAPARO, Roberto; NORDMARK, Anna; FINNSTRÖM, Niklas et al.Basic & clinical pharmacology & toxicology (Print). 2007, Vol 100, Num 4, pp 240-248, issn 1742-7835, 9 p.Article

Characterization of human liver microsomal cytochrome P450 involved in the reductive metabolism of zonisamideNAKASA, H; KOMIYA, M; OHMORI, S et al.Molecular pharmacology. 1993, Vol 44, Num 1, pp 216-221, issn 0026-895XArticle

CYP3A Time-Dependent Inhibition Risk Assessment Validated with 400 Reference DrugsZIMMERLIN, Alfred; TRUNZER, Markus; FALLER, Bernard et al.Drug metabolism and disposition. 2011, Vol 39, Num 6, pp 1039-1046, issn 0090-9556, 8 p.Article

Identification of a Cranberry Juice Product that Inhibits Enteric CYP3A-Mediated First-Pass Metabolism in HumansNGO, Ngoc; ZHIXIA YAN; GRAF, Tyler N et al.Drug metabolism and disposition. 2009, Vol 37, Num 3, pp 514-522, issn 0090-9556, 9 p.Article

Characterization of androgen-regulated expression of CYP3A5 in human prostateMOILANEN, Anne-Mari; HAKKOLA, Jukka; VAARALA, Markku H et al.Carcinogenesis (New York. Print). 2007, Vol 28, Num 5, pp 916-921, issn 0143-3334, 6 p.Article

Inhibitory effects of fruit juices on CYP3A activityKIM, Hyunmi; YOON, Yune-Jung; SHON, Ji-Hong et al.Drug metabolism and disposition. 2006, Vol 34, Num 4, pp 521-523, issn 0090-9556, 3 p.Article

The Influence of CYP3A5 Expression on the Extent of Hepatic CYP3A Inhibition Is Substrate-Dependent : An in Vitro-in Vivo EvaluationISOHERRANEN, Nina; LUDINGTON, Shana R; WATKINS, Paul B et al.Drug metabolism and disposition. 2008, Vol 36, Num 1, pp 146-154, issn 0090-9556, 9 p.Article

Assessment of ifosfamide pharmacokinetics, toxicity, and relation to CYP3A4 activity as measured by the erythromycin breath test in patients with sarcomaCHUGH, Rashmi; WAGNER, Thomas; GRIFFITH, Kent A et al.Cancer. 2007, Vol 109, Num 11, pp 2315-2322, issn 0008-543X, 8 p.Article

Lack of in vivo correlation between indinavir and saquinavir exposure and cytochrome P450 3A phenotype as assessed with oral midazolam as a phenotype probeROBERTSON, Sarah M; FORMENTINI, Elizabeth; ALFARO, Raul M et al.Pharmacotherapy. 2006, Vol 26, Num 8, pp 1051-1059, issn 0277-0008, 9 p.Article

Evaluation of Various Static In Vitro-In Vivo Extrapolation Models for Risk Assessment of the CYP3A Inhibition Potential of an Investigational DrugVIEIRA, Md L. T; KIRBY, B; HALL, S. D et al.Clinical pharmacology and therapeutics. 2014, Vol 95, Num 2, pp 189-198, issn 0009-9236, 10 p.Article

Evaluation of Various Static and Dynamic Modeling Methods to Predict Clinical CYP3A Induction Using In Vitro CYP3A4 mRNA Induction DataEINOLF, H. J; CHEN, L; ZHAO, P et al.Clinical pharmacology and therapeutics. 2014, Vol 95, Num 2, pp 179-188, issn 0009-9236, 10 p.Article

A Novel Maturation Function for Clearance of the Cytochrome P450 3A Substrate Midazolam from Preterm Neonates to AdultsINCE, Ibrahim; DE WILDT, Saskia N; WANG, Chengueng et al.Clinical pharmacokinetics. 2013, Vol 52, Num 7, pp 555-565, issn 0312-5963, 11 p.Article

A Physiologically Based Pharmacokinetic Modeling Approach to Predict Disease―Drug Interactions: Suppression of CYP3A by IL-6MACHAVARAM, K. K; ALMOND, L. M; ROSTAMI-HODJEGAN, A et al.Clinical pharmacology and therapeutics. 2013, Vol 94, Num 2, pp 260-268, issn 0009-9236, 9 p.Article